Colonic biopsy-associated microbial signatures are predictive of response to anti-TNFα biological therapy in Crohn’s disease

IntroductionCrohn’s disease (CD) is commonly treated with biologic therapies, including anti-TNFα agents, vedolizumab (VDZ), and ustekinumab (USTE), yet only a subset of patients respond to these treatments. This study aimed to evaluate the potential of the gut microbiome to predict treatment respon...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Konstantina Zafeiropoulou, Ishtu L. Hageman, Tianqi Mu, Mark Davids, Andrew Y. F. Li Yim, Vincent W. Joustra, Theodorus B. M. Hakvoort, Jack Satsangi, Konstantinos Chronas, Pim J. Koelink, Manon E. Wildenberg, Rene M. van den Wijngaard, Geert R. D’Haens, Wouter J. de Jonge
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2026-03-01
Schriftenreihe:	Frontiers in Cellular and Infection Microbiology
Schlagworte:	adalimumab (ADA) adherent microbiome biomarkers infliximab (ifx) macrophages
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fcimb.2026.1741002/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!